Despite the fact that SLC22A16 has received a considerable amount of attention with respect to platinum accumulation and resistance in various types of cancer [62, 63], no studies have explained its involvement in urinary bladder cancer, which calls for more research investigating its significance in platinum-treated UBC patients. Here, SLC22A16 is linked to cancer.